寡核苷酸单体
Search documents
江苏诺泰澳赛诺生物制药股份有限公司关于使用闲置募集资金进行现金管理的公告
Shang Hai Zheng Quan Bao· 2026-01-16 18:48
Investment Management Announcement - The company plans to use idle raised funds for cash management, with a maximum amount of RMB 50 million, to enhance the efficiency of fund usage and increase returns for the company and its shareholders [2][3][12] - The investment will be in low-risk, high-liquidity, and capital-preserving products such as structured deposits and time deposits [2][7] - The investment period is valid for 12 months from the board's approval date, and funds can be rolled over within this limit [4][12] Financial Performance and Management - In the last 12 months, the company has utilized a total of RMB 150.7 million in cash management, with a total return of RMB 286,200, all of which has been returned to the designated fund account without any overdue situations [19] - The company has a history of managing idle funds effectively, ensuring that it does not affect the normal operation of its investment projects [17][19] Risk Management - The company acknowledges that financial markets are influenced by macroeconomic factors, and it will adjust its investment strategies accordingly to mitigate risks [14][15] - The board has authorized the chairman and staff to handle related matters and sign necessary documents for cash management [8][12] Project Delay Announcement - The company has postponed the timeline for the "oligonucleotide monomer industrialization project" to December 2026, ensuring that the project remains within the original investment scope and does not affect the overall business operations [44][46][48] - The delay is attributed to various uncontrollable factors affecting construction progress and equipment procurement [46] Credit Facility and Guarantee - The company plans to apply for a total credit facility of up to RMB 600 million for operational needs in 2026, including various types of loans and guarantees [54][55] - The company will provide guarantees for its subsidiaries, with a maximum guarantee amount of RMB 100 million, ensuring that the financial health of the subsidiaries is maintained [55][59]